SEC Form 4 · accession 0001209191-19-006220
IRONWOOD PHARMACEUTICALS INC · IRWD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gina Consylman
Officer — Chief Financial Officer
Period of report
Jan 29, 2019
Accepted (ET)
Jan 31, 2019 · 5:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001446847
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Jan 29, 2019 | A | 72,500 | $0.00 | A | 168,861 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option(Right to Buy)F2 | $12.90 | Jan 29, 2019 | A | 145,000 | A | — | Jan 29, 2029 | Class A Common Stock | 145,000 | 145,000 | D |
Explanation of responses
- F1The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
- F2The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2019.